Subscribe - Individual

Subscribe - Biotech Premium (Corporate)


November 20th, 2023

Adalta Finalises Data for Licensing with Lead Compound AD214

Adalta (IAD: $0.018) is developing the next generation of therapeutic antibodies. These compounds are human protein drug candidates based on the unique structure of shark antibodies. This design combines the features of small molecule drugs (that can access binding sites conventionally difficult to access) and antibodies (which are characterized by the ability for highly specific binding).

December 19th, 2022

Adalta Returns to IV Formulation for AD-214

Last year novel antibody company Adalta (1AD: $0.044) announced that it would be moving to develop an inhaled formulation of its lead drug candidate, AD-214. This followed preclinical studies that showed high accumulation of the compound in the liver, although no liver toxicity was observed in patients in the Phase I study.

July 27th, 2021

Adalta Moves to Inhaled Delivery for AD-214

Biologics drug development company Adalta (1AD: $0.09) has announced that its lead drug candidate, AD-214, will now be developed as an inhaled drug rather than a systemically delivered injected therapy.

The key reason for the change is that preclinical imaging studies with a radiolabelled version of AD-214 showed high accumulation levels (more than half the administered dose) in the liver. The reasons for strong binding affinity in the liver are unknown at this point, but it is not related to the i-body platform with the rapid distribution to the liver seen only with this drug candidate.

June 15th, 2021

Adalta Progresses GE Collaboration and Sets Clear Milestones for Path Ahead

Adalta (1AD: $0.155) has progressed its collaboration with GE Healthcare for its cancer treatment diagnostic.

In September Adalta signed a commercial deal with GE to find i-bodies using its unique technology that could very specifically bind to the enzyme granzyme B which is produced by activated T-cells.

Adalta has now identified several relevant i-bodies which will progress into preclinical development.

March 15th, 2021

Adalta Phase Ia Results – Multiple Positive Findings

Last week Adalta (1AD: $0.175) provided details of the successful completion of its Phase Ia trial with its lead antibody drug candidate, AD-214. The company will now move into two additional Phase I studies, one in healthy volunteers and the second in patients with fibrotic lung diseases.

February 15th, 2021

Adalta’s Prospects Improve

Adalta’s (1AD) competitive prospects improved recently when a high profile drug, ziritaxestat, being developed by Galapagos and Gilead Sciences for idiopathic pulmonary fibrosis (IPF), was discontinued.